All In MedTech

Device Trial Radar · NCT00406133

Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes

A Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) in the Management of Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

451

Actual

Start

Dec 2006

Primary completion

Jul 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Jaeb Center for Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
JDRF Artificial Pancreas Project
First posted
Dec 4, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects with intensively-treated type 1 diabetes and glycated hemoglobin (HbA1c) 7.0%-10.0% in 3 age groups (\>25, 15-24, 8-14) will be randomized to a continuous glucose monitoring (CGM) group or control group. The primary outcome is change in HbA1c after 26 weeks. A parallel randomized trial is being conducted for a second cohort with HbA1c \<7.0% that will follow an identical protocol to that of the first cohort with HbA1c \>=7.0%. The \>=7.0% trial was specifically designed and statistically powered to compare separately the impact of continuous versus standard intensive glucose monitoring in the three age groups. Both trials used standardized treatment algorithms and equivalent frequent contacts with subjects in both the CGM and control group. After completion of the 26-week trial, the CGM group continues to use CGM for another 26 weeks to evaluate whether any beneficial effect seen in the first 6 months is sustained with longer-term use and less intensive contact and the control group initiates CGM use with less intensive contact after the first month than was provided at initiation of CGM use in the CGM group in the randomized trial.

Conditions

  • Type 1 Diabetes

Interventions

  • Continuous glucose monitorDevice

    Daily use of a continuous glucose monitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c >=7.0% Cohort)Time frame: Baseline and 26 weeks
  2. Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%)Time frame: Baseline and 26 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Beverly Hills, California

  • Kaiser Permanente

    San Diego, California

  • Stanford University

    Stanford, California

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.